New drug cocktail aims to shrink Hard-to-Treat head and neck cancers

NCT ID NCT07581821

Recruiting now Disease control Sponsor: Ming-Yuan Chen Source: ClinicalTrials.gov ↗

First seen May 13, 2026 · Last updated May 14, 2026 · Updated 1 time

Summary

This study tests a combination of three drugs (sintilimab, anlotinib, and a taxane chemotherapy) in 33 adults with nasopharyngeal cancer that has returned or spread and hasn't responded to prior treatments. The goal is to see if this combo can shrink tumors and control the disease. Participants must be 18-65 and have a specific type of nasopharyngeal carcinoma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fifth Affiliated Hospital of Sun Yat-sen University Zhuhai, Guangdong, China, 519000
RECRUITING

Zhuhai, Guangdong, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA